(Bloomberg) On the (Paxlovid) rebound, Pfizer Inc.’s antiviral medication caused recurrences or prolonged infections more often in real life than in clinical studies. (A rebound of coronavirus occurred in 2.3% of patients on Paxlovid versus 1.7% receiving placebo in a late-stage trial, Pfizer scientists said in September.)
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.